ArticleInternational journal of particle therapy2026
Outcomes After Fast Neutron Therapy for Locally Advanced Base of Tongue Adenoid Cystic Carcinoma.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Base of tongue (BOT) adenoid cystic carcinoma (ACC) is a rare, locally aggressive malignancy that is typically associated with a high rate of disease recurrence. Surgery alone is rarely curative and highly morbid. Outcomes of systemic therapies and low linear energy transfer radiation therapy (RT) are generally poor. Fast neutron therapy (NRT), a form of high linear energy transfer radiation, is advantageous in treating radioresistant salivary gland malignancies. Long-term cancer control and swallowing outcomes in patients with BOT ACC treated with NRT were retrospectively reviewed. Methods: Between 1994 and 2023, 63 patients ≥18 years (median age 61) with biopsy-confirmed BOT ACC, not treated previously with surgery or RT, underwent 3D-conformal NRT or intensity-modulated neutron therapy (IMNT) for localized M0 (77.8%) or M1 (22.2%) disease. Most patients had (T3-4) primary tumors. Kaplan-Meier method was used to estimate locoregional recurrence-free (LRFS), distant metastasis-free, and overall survival. Late toxicities (≥90 days after NRT) were reported per Common Terminology Criteria for Adverse Events v5.0. Treatment-related and post-treatment percutaneous endoscopic gastrotomy (PEG) tube utilization was evaluated. Results: For the entire cohort, 5-year LRFS was 53.4%, and 5-year overall survival was 75.1%. Among M0 patients, 3-year LRFS was 72.4%, 5-year LRFS was 59.4%, and 5-year distant metastasis-free was 44.1%. Prophylactic PEG tubes were placed in 58.1% of patients; 14.5% remained PEG-dependent ≥90 days post-treatment. Common toxicities included xerostomia and dysphagia. Among evaluable patients, 33.3% required PEG placement after 90 days due to disease or salvage therapy. Neither patient treated with IMNT required long-term PEG use. Conclusions: This is the first study to report clinical outcomes of NRT for BOT ACC. Swallowing outcomes were acceptable, with a low rate of persistent PEG dependence. NRT achieved significant locoregional control in many locally advanced primary tumors. Additional improvements in the therapeutic ratio and functional outcomes may be achievable with IMNT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.